Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Publications FSGS

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

View
Publications

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

View
Publications IgAN

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

View
Publications IgAN

Clinicopathological Characteristics of Adult IgA Nephropathy in the United States

View
Publications IgAN

Impact of Proteinuria and Kidney Function Decline on Health Care Costs and Resource Utilization in Adults With IgA Nephropathy in the United States: A Retrospective Analysis

View
Publications Nephrology

Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: An Open-Label Drug–Drug Interaction Study in Healthy Adults

View
Publications Nephrology

Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis

View
Publications CTX

Allelic prevalence and geographic distribution of cerebrotendinous xanthomatosis

View
Publications FSGS

Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial

View
Publications HCU

Accurate 24‐h urine cystine quantification for patients on cystine‐binding thiol drugs

View
Publications FSGS

Efficacy and Safety of Immunosuppressive Therapy in Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis

View
Publications IgAN

International Physicians Delphi Survey: Managing Patients With IgA Nephropathy

View
Publications ALGS

Therapeutics Development for Alagille Syndrome

View